Aspirin for healthy aging: what ASPREE actually tested

Start with the reason aspirin is being considered

Aspirin sounds like a simple addition to a healthy-aging routine: familiar, inexpensive and available without a prescription. That familiarity can obscure the decision that matters. Preventing a first cardiovascular event in someone without established cardiovascular disease is a different question from treatment after an event. ASPREE studied the former situation in older adults. Its findings challenge the idea that an otherwise healthy person should add aspirin simply because preventing problems sounds sensible. ^{[1] [2]}

This article explains the evidence behind that distinction. It is not a reason to change a prescribed regimen on your own. If you already take aspirin, first establish why it was recommended. A useful medication review begins with that indication, the other medicines you use and the outcomes the treatment is intended to prevent. The name on the bottle alone does not tell you whether the ASPREE population resembles your situation.

For a different prevention population, compare how an established cardiovascular-disease population changes a trial.

The trial measured life without dementia or persistent disability

ASPREE assigned 19,114 community-dwelling adults in Australia and the United States to 100 milligrams of enteric-coated aspirin daily or placebo. Participants generally were at least 70; the minimum was 65 for Black and Hispanic participants in the United States. They entered without cardiovascular disease, dementia or physical disability. The primary outcome combined death, dementia and persistent physical disability. This is closer to a healthspan question than a change in a laboratory number. ^[1]

After median follow-up of 4.7 years, that combined outcome occurred at 21.5 versus 21.2 events per 1,000 person-years, aspirin versus placebo. The hazard ratio was 1.01, with a 95% confidence interval from 0.92 to 1.11. There was no demonstrated improvement in disability-free survival. Final-year adherence was around 62% and 64%, respectively, so the result concerns assignment to a sustained regimen with imperfect adherence, rather than an idealized experiment in which everyone always took every tablet. ^[1]

Bleeding belongs in the same comparison as cardiovascular benefit

The cardiovascular analysis counted fatal coronary heart disease, nonfatal heart attack, fatal or nonfatal stroke, or hospitalization for heart failure. Rates were 10.7 versus 11.3 per 1,000 person-years; the hazard ratio was 0.95, with a confidence interval of 0.83 to 1.08. That comparison did not establish a significant cardiovascular reduction. Major hemorrhage, meanwhile, occurred at 8.6 versus 6.2 per 1,000 person-years, hazard ratio 1.38, confidence interval 1.18 to 1.62. ^[2]

Those are event rates over accumulated follow-up, not percentages of people harmed each year. They also concern different outcomes, so subtracting them cannot produce a personalized net-benefit score. The practical point is simpler: the trial did not show the hoped-for cardiovascular advantage while it did show increased major bleeding. A preventive purchase should be judged on that whole comparison, not only on a plausible mechanism or a familiar historical reputation.

The mortality finding needs its original caution

A companion report observed all-cause mortality rates of 12.7 versus 11.1 per 1,000 person-years, with a hazard ratio of 1.14 and a 95% confidence interval from 1.01 to 1.29. Cancer deaths contributed most to the observed excess. The authors explicitly described the finding as unexpected in the context of earlier studies and urged caution in interpretation. It is evidence to acknowledge, not an invitation to claim that aspirin inevitably causes cancer in an individual user. ^[3]

Keeping uncertainty attached to a result is especially important when a dramatic headline could prompt a sudden medication change. The trial measured group outcomes in a defined population over a limited period. It cannot identify the cause of a particular reader’s symptom or establish what would happen after stopping treatment. Nor does it tell us that every dose, age group or medical indication has the same balance. Those distinctions protect a useful result from being stretched into an unhelpful universal rule.

Current preventive guidance separates starting from continuing

The US Preventive Services Task Force recommends against initiating low-dose aspirin for primary prevention of cardiovascular disease in adults aged 60 or older. For adults 40 to 59 with at least 10% estimated ten-year cardiovascular risk, it describes an individual decision with a small net benefit, applying to people without increased bleeding risk. The recommendation concerns prevention in people without known cardiovascular disease; it does not replace condition-specific treatment advice. ^[4]

The Task Force also tells people already taking aspirin to discuss questions about continuing or stopping with their clinician rather than discontinuing without consultation. ^[4] That makes the next step a medication conversation, not a shopping decision. Bring the actual dose, frequency and reason for use. Ask whether the original preventive rationale still fits your age and history, and whether another prescriber is relying on the medicine for a separate indication.

Make the prevention plan more specific than adding a tablet

A clear prevention plan names the risk it addresses and the evidence that the chosen action improves a meaningful outcome. A home blood-pressure record, for example, is useful only when its interpretation and follow-up are defined. Similarly, a long blood panel is not itself a treatment plan. The same standard applies to aspirin: an accessible product should not bypass the question of who benefits, who may be harmed and who will review the decision.

ASPREE offers a useful lesson for the broader longevity market. A treatment can have a persuasive biological rationale and still fail to improve the combined outcome people care about. Before paying for another preventive service or adding a recurring product, ask what outcome was tested, in whom and over what period. The answer may support a focused purchase, an appropriate clinical review or simply avoiding an addition that has not earned its place. That is a stronger definition of prevention than making a routine longer.

For a measurement connected to an actionable follow-up plan, read home blood-pressure monitoring.

To evaluate what a broad testing subscription adds, compare Function Health’s testing model.